Roles of cMET/ErbB3 activation and overexpression in the development or resistance to EGFR inhibitors in NSCLC patients.

被引：0
|
作者：
Ahn, Myung-Ju
Park, Silvia
Sun, Jong-Mu
Ahn, Jin Seok
Park, Keunchil
Langley, Emma J.
Kim, Phillip Sangwook
Singh, Sharat
Lockton, Steve
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
[3] Prometheus Labs Inc, San Diego, CA USA
[4] Prometheus Therapeut & Diagnost, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11113
引用
收藏
页数：1
相关论文
共 50 条
  • [21] MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer
    Yuanzhou Zhang
    Shunshun Liang
    Bowen Xiao
    Jingying Hu
    Yechun Pang
    Yuling Liu
    Juan Yang
    Junpin Ao
    Lin Wei
    Xiaoying Luo
    Cell Death & Disease, 13
  • [22] Discovery of ERBB3 inhibitors for non-small cell lung cancer (NSCLC) via virtual screening
    Rong Guo
    Yuan Zhang
    Xiao Li
    Xinrui Song
    Da Li
    Yong Zhao
    Journal of Molecular Modeling, 2016, 22
  • [23] Disruption of neuregulin, ErbB2 and ErbB3 genes: Cardiac and neural abnormalities illustrate roles in development.
    Erickson, SL
    OShea, KS
    Moore, MW
    MOLECULAR BIOLOGY OF THE CELL, 1996, 7 : 669 - 669
  • [24] Discovery of ERBB3 inhibitors for non-small cell lung cancer (NSCLC) via virtual screening
    Guo, Rong
    Zhang, Yuan
    Li, Xiao
    Song, Xinrui
    Li, Da
    Zhao, Yong
    JOURNAL OF MOLECULAR MODELING, 2016, 22 (06) : 1 - 9
  • [25] ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors
    Luigi Fattore
    Debora Malpicci
    Emanuele Marra
    Rosalba Camerlingo
    Giuseppe Roscilli
    Francesca Belleudi
    Antoni Ribas
    Rita Mancini
    Maria Rosaria Torrisi
    Luigi Aurisicchio
    Paolo Antonio Ascierto
    Gennaro Ciliberto
    Journal of Translational Medicine, 13 (Suppl 1)
  • [26] Clinical efficacy of HER3 partners' inhibitors in ERBB3 mutated cancer patients
    Verlingue, L.
    Massard, C.
    Hollebecque, A.
    Alvarez, E. Castanon
    Postel-Vinay, S.
    Angevin, E.
    Armand, J-P.
    Aspeslagh, S.
    Varga, A.
    Ratislav, B.
    Gazzah, A.
    Michot, J-M.
    Lacroix, L.
    De Baere, T.
    Marabelle, A.
    Soria, J-C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients
    Reinmuth, Niels
    Jauch, Anna
    Xu, Elizabeth Chang
    Muley, Thomas
    Granzow, Martin
    Hoffmann, Hans
    Dienemann, Hendrik
    Herpel, Esther
    Schnabel, Philipp A.
    Herth, Felix J. F.
    Gottschling, Sandra
    Lahm, Harald
    Steins, Martin
    Thomas, Michael
    Meister, Michael
    LUNG CANCER, 2008, 62 (02) : 193 - 201
  • [28] Landscape of EGFR-dependent and independent mechanisms of osimertinib resistance in EGFR-mutant NSCLC patients.
    Le, Xiuning
    Puri, Sonam
    Negrao, Marcelo Vailati
    Nilsson, Monique B.
    Robichaux, Jacqulyne Ponville
    Boyle, Theresa A.
    Hicks, James Kevin
    Roarty, Emily
    Rinsurongkawong, Waree
    Glisson, Bonnie S.
    Zhangx, Jianjun
    Papadimitrakopoulou, Vassiliki
    Gray, Jhanelle Elaine
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] ERBB2 AND ERBB3 EXPRESSION IN RESECTED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS)
    Freixinos, Victor
    Salcedo, Maite
    Tallada, Natalia
    Murtra-Garrell, Nuria
    Navarro, Alejandro
    Martinez, Pablo
    Cedres, Susana
    Teixido, Cristina
    Hernandez-Losa, Javier
    Lopez, Eva
    Montero, M. A.
    Peg, Vicente
    Pallisa, Esther
    Canela, Mercedes
    Felip, Enriqueta
    Ramon Y Cajal, Santiago
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1063 - S1064
  • [30] Expression of ErbB2 and ErbB3 in resected non- small cell lung cancer (NSCLC) patients (pts)
    Felip, E.
    Salcedo, M.
    Murtra-Garrell, N.
    Navarro, A.
    Teixido, C.
    Hernandez-Losa, J.
    Cedres, S.
    Martinez, P.
    Lopez, E.
    Montero, M. A.
    Freixinos, V.
    Argiles, G.
    Nunez, I.
    Peg, V.
    Pallisa, E.
    Canela, M.
    Tabernero, J.
    Ramon y Cajal, S.
    Tallada, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345